On 24 December 2024, Biocon announced that the company and its European partner, Zentiva, have received Decentralised Procedure (DCP) approval for liraglutide in the European Union. The approval is for the generic versions of Novo Nordisk’s Victoza®, to treat type-2 diabetes, and Saxenda®, used in the treatment of weight management.
Biocon’s liraglutide became the first UK approved generic to Novo Nordisk’s Victoza® in March 2024. The first EU approved generic liraglutide was Adalvo’s liraglutide pre-filled pen in June 2024.
On 24 May 2024, Biocon announced that it signed an exclusive licensing and supply agreement with Korea’s Handok Inc for the commercialisation in South Korea of its synthetic liraglutide.